by | Oct 7, 2023 | Uncategorized
Source: CureToday articles A new T-cell therapy showed benefits in patients with relapsed/refractory multiple myeloma. Read More
by | Oct 5, 2023 | Uncategorized
Source: CureToday articles A low rate of high-grade blood-related side effects following treatment with induction Dara-KRd and consolidation double transplant was discovered in a trial for patients with high-risk, newly diagnosed multiple myeloma. Read...
by | Oct 3, 2023 | Uncategorized
Source: CureToday articles An expert sat down with CURE® and discussed how stem cells are collected before a patient with myeloma undergoes a stem cell transplant. Read More
by | Oct 3, 2023 | Uncategorized
Source: CureToday articles Patients with multiple myeloma who are undergoing systemic treatment can see improvements from exercise, a recent study shows. Read More
by | Oct 2, 2023 | Uncategorized
Prophylactic IV immunoglobulin supplementation reduced the risk for severe infections by 90% among adults receiving a B-cell maturation antigen-directed bispecific antibody for treatment of multiple myeloma, study results showed.The findings — published in Blood...
by | Oct 1, 2023 | Uncategorized
Source: CureToday articles Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status. Read...
